Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841756 | 0.86 | MAOB (0.54) | MAOBMAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL6841444 | 0.85 | MAOB (0.39) | MAOBMAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL6841201 | 0.78 | ALDH1A1 (0.55) | MAOBMAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL5451796 | 0.72 | ALDH1A1 (0.70) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6815456 | 0.70 | MAOB (0.51) | MAOBMAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL6944649 | 0.70 | MAOB (0.48) | MAOBMAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL15484146 | 0.70 | IDO1 (0.75) | MAOBMAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL7691721 | 0.69 | HDAC1 (0.43) | MAOBMAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL7098462 | 0.69 | MAOB (0.61) | MAOBMAPTALDH1A1NPSR1MEN1 | |
| SCHEMBL6815450 | 0.67 | ALDH1A1 (0.54) | MAOBMAPTALDH1A1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | WU YONG-QIAN (US) | 2004-08-12 | — | — | US | claimed |
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | WU YONG-QIAN (US) | 2004-08-12 | — | — | US | disclosed |
| US-6656971-B2 | Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions | GUILFORD PHARMACEUTICALS INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | MAOB 1073/4885MAPT 1908/4885ALDH1A1 2070/4885 |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | MAOB 1073/4885MAPT 1908/4885ALDH1A1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.